While valuations across the pharmaceutical industry have soared this year -- with shares of diversified giants like Merck (NYSE:MRK) and Pfizer up significantly -- Bristol-Myers Squibb (NYSE:BMY) in particular has been on a tear recently. In the last 12 months, its shares are up a whopping 40%. However, despite all of the promising drugs that the company is developing in clinical trials, is there any upside left in this stock today? In the following video, analysts David Williamson and Max Macaluso discuss three reasons to consider selling Bristol-Myers.